The letter was signed by Alberto Gutierrez, director of the Office of Invitro Diagnostics and Radiological Health at the Center for Devices and Radiological Health. Elaborating on his concerns, Gutierrez explained that he remained skeptical of the company's service.
While the Personal Genome Service is marketed as a tool to empower consumers — by informing them of certain genetic risks and providing them with knowledge that would help them make better treatment choices — Gutierrez wrote, "We still do not have any assurance that the firm has analytically or clinically validated the PGS for its intended uses. ... Therefore, 23andMe must immediately discontinue marketing the PGS until such time as it receives FDA marketing authorization for the device."
In a brief response to the FDA's letter, posted on 23andMe's website, the company wrote, "We recognize that we have not met the FDA's expectations regarding timeline and communication regarding our submission. Our relationship with the FDA is extremely important to us and we are committed to fully engaging with them to address their concerns."
This story contains 233 words.
Stories older than 90 days are available only to subscribing members. Please help sustain quality local journalism by becoming a subscribing member today.
If you are already a subscriber, please log in so you can continue to enjoy unlimited access to stories and archives. Subscriptions start at $5 per month and may be cancelled at any time.